Subtopic Deep Dive
BRCA2 Mutations in Ovarian Cancer
Research Guide
What is BRCA2 Mutations in Ovarian Cancer?
BRCA2 mutations are germline or somatic alterations in the BRCA2 gene that significantly elevate ovarian cancer risk and influence therapeutic responses in carriers.
BRCA2 mutations impair homologous recombination repair, leading to genomic instability and ovarian tumorigenesis. Studies document elevated ovarian cancer incidence among carriers, with PARP inhibitors like olaparib showing efficacy (Fong et al., 2009; 3582 citations). Over 20 papers in the provided list address BRCA-related ovarian cancer risks and treatments.
Why It Matters
BRCA2 mutation status guides risk-reducing salpingo-oophorectomy, reducing ovarian cancer risk by up to 80% in carriers (Kauff et al., 2002; 1244 citations). Olaparib monotherapy extends progression-free survival in BRCA2-mutated advanced ovarian cancers (Kaufman et al., 2014; 1651 citations). These insights enable precision medicine, including PARP inhibitor therapy, improving outcomes in 15-20% of ovarian cancer patients with germline BRCA mutations (Torre et al., 2018; 3619 citations).
Key Research Challenges
Heterogeneous Mutation Spectrum
BRCA2 mutations vary widely, complicating risk prediction across populations. Kuchenbaecker et al. (2017; 2687 citations) highlight location-specific risks using prospective data. Identifying pathogenic variants requires comprehensive genomic profiling.
PARP Inhibitor Resistance
Tumors develop resistance to olaparib despite initial BRCA2 synthetic lethality. Fong et al. (2009; 3582 citations) established PARP inhibition efficacy, but long-term response durability remains limited. Secondary reversion mutations restore homologous recombination.
Survival Outcome Variability
BRCA2 carriers show improved survival with platinum therapy, but prognostic factors differ. Torre et al. (2018; 3619 citations) report 14,070 annual US ovarian cancer deaths, underscoring need for better biomarkers. Conflicting data on mutation type and progression-free survival persist.
Essential Papers
Ovarian cancer statistics, 2018
Lindsey A. Torre, Britton Trabert, Carol DeSantis et al. · 2018 · CA A Cancer Journal for Clinicians · 3.6K citations
Abstract In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an ove...
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · 2017 · JAMA · 2.7K citations
These findings provide estimates of cancer risk based on BRCA1 and BRCA2 mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mut...
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton, Karen A. Pooley, Alison M. Dunning et al. · 2007 · Nature · 2.3K citations
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
Mieke Kriege, Cecile T.M. Brekelmans, C. Boetes et al. · 2004 · New England Journal of Medicine · 1.7K citations
MRI appears to be more sensitive than mammography in detecting tumors in women with an inherited susceptibility to breast cancer.
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · 2014 · Journal of Clinical Oncology · 1.7K citations
Purpose Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) –associated breast and ovarian cancers. We evaluated the efficacy and safety o...
Awareness and current knowledge of breast cancer
Muhammad Akram, Mehwish Iqbal, Muhammad Daniyal et al. · 2017 · Biological Research · 1.3K citations
Breast cancer remains a worldwide public health dilemma and is currently the most common tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in breast imaging has...
Reading Guide
Foundational Papers
Start with Fong et al. (2009; 3582 citations) for PARP inhibition mechanism in BRCA carriers, then Kauff et al. (2002; 1244 citations) for surgical risk reduction evidence.
Recent Advances
Study Kuchenbaecker et al. (2017; 2687 citations) for prospective risk estimates and Kaufman et al. (2014; 1651 citations) for olaparib monotherapy outcomes.
Core Methods
Core techniques include PARP inhibitor assays (Fong et al., 2009), prospective cohort risk modeling (Kuchenbaecker et al., 2017), and salpingo-oophorectomy outcome analysis (Kauff et al., 2002).
How PapersFlow Helps You Research BRCA2 Mutations in Ovarian Cancer
Discover & Search
Research Agent uses searchPapers and exaSearch to find BRCA2 ovarian cancer literature, revealing Fong et al. (2009) as a cornerstone with 3582 citations on PARP inhibition. citationGraph traces forward citations to Kaufman et al. (2014), while findSimilarPapers identifies related olaparib trials.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation spectra from Kuchenbaecker et al. (2017), then verifyResponse with CoVe checks claims against Torre et al. (2018) statistics. runPythonAnalysis performs survival curve meta-analysis via Kaplan-Meier estimation on extracted data, with GRADE grading for evidence quality on PARP efficacy.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-Fong et al. (2009), flagging contradictions in survival data. Writing Agent uses latexEditText for manuscript drafting, latexSyncCitations to integrate Kauff et al. (2002), and latexCompile for PDF output; exportMermaid visualizes BRCA2 repair pathway diagrams.
Use Cases
"Extract survival data from BRCA2 ovarian cancer papers and plot Kaplan-Meier curves."
Research Agent → searchPapers('BRCA2 ovarian survival') → Analysis Agent → readPaperContent(Kuchenbaecker 2017) → runPythonAnalysis(pandas survival analysis, matplotlib plot) → researcher gets publication-ready KM curves with p-values.
"Draft a review section on PARP inhibitors in BRCA2 ovarian cancer with citations."
Synthesis Agent → gap detection(olaparib resistance) → Writing Agent → latexEditText('PARP section') → latexSyncCitations(Fong 2009, Kaufman 2014) → latexCompile → researcher gets LaTeX PDF with formatted references and figures.
"Find code for BRCA2 mutation analysis from related papers."
Research Agent → paperExtractUrls(ovarian genomics papers) → paperFindGithubRepo → githubRepoInspect → researcher gets verified Python scripts for variant calling and annotation pipelines.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ BRCA papers via searchPapers → citationGraph → GRADE grading, producing structured report on mutation prevalence. DeepScan applies 7-step analysis with CoVe checkpoints to verify olaparib efficacy claims from Fong et al. (2009). Theorizer generates hypotheses on BRCA2 reversion mutations from literature patterns.
Frequently Asked Questions
What defines BRCA2 mutations in ovarian cancer?
BRCA2 mutations are loss-of-function variants disrupting DNA repair, increasing ovarian cancer risk 10-30 fold in carriers (Kuchenbaecker et al., 2017).
What are key therapeutic methods?
PARP inhibitors like olaparib exploit synthetic lethality in BRCA2-deficient tumors (Fong et al., 2009; Kaufman et al., 2014).
What are major papers?
Fong et al. (2009; 3582 citations) established PARP inhibition; Torre et al. (2018; 3619 citations) provides epidemiology; Kauff et al. (2002; 1244 citations) validates risk reduction surgery.
What open problems exist?
Overcoming PARP resistance and standardizing mutation risk models across ethnicities remain unsolved, with heterogeneous spectra noted (Kuchenbaecker et al., 2017).
Research BRCA gene mutations in cancer with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching BRCA2 Mutations in Ovarian Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the BRCA gene mutations in cancer Research Guide